06:57:00 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Theralase Technologies Inc
Symbol TLT
Shares Issued 79,907,709
Close 2014-07-16 C$ 0.31
Market Cap C$ 24,771,390
Recent Sedar Documents

Theralase applies for U.S. patent on anti-cancer laser

2014-07-17 07:45 ET - News Release

Mr. Roger Dumoulin-White reports

THERALASE ADVANCES INTELLECTUAL PROPERTY OF ANTI-CANCER TECHNOLOGY

Theralase Technologies Inc. has applied for a U.S. patent for a multiwavelength laser light source that is capable of safely and effectively activating its patented and patent-pending photodynamic compounds (PDCs) in the destruction of cancer at various tissue depths.

Theralase's PDCs are able to be activated by laser wavelengths ranging from the visible spectrum to the near-infrared (NIR) spectrum. This newly conceived multiwavelength laser system is able to activate the PDCs from a few hundred microns (millionths of a metre) to 10 centimetres in depth allowing oncologists the ability to target surface as well as deep cancerous tumours.

Dr. Arkady Mandel, chief scientific officer of Theralase, stated: "The new multiwavelength laser system combined with Theralase's PDCs presents the first opportunity for an oncologist to be able to provide a fully patient-specific photo dynamic therapy (PDT) treatment. The treatment is customizable for a patient, by optimizing the quantity of PDC delivered and the quantity and wavelength of laser light delivered based on the disease characterization, which includes: the depth of the cancer, the localization of the cancer in the tissues and the stage of the progression of the disease. In terms of bladder cancer, for example, patients diagnosed with a non-muscle-invasive bladder cancer (NMIBC) that is fairly superficial would benefit from activation of the PDCs that has localized in their cancer cells in the lower visible range (that is blue, green wavelengths). Patients, however, with more advanced muscle-invasive bladder cancer (MIBC) that presents deeper in the organ, would best be served by having the PDCs in their cancer cells activated in the higher visible ranges (that is red to near-infrared wavelengths). The clear advantage of the combination of Theralase PDCs and the customized TLC-3000 laser delivery system is truly personalized care for the patient. As a result, Theralase's approach can eliminate unnecessary treatments, minimize the potential for adverse events and ultimately improve patient outcomes. Based on the recent discovery of the cancer-specific memory effect, where Theralase demonstrated an ability for the PDCs to influence the immune response preventing further cancerous tumours from occurrence, the technology may now have an opportunity to destroy the primary tumour with high precision and then simultaneously program the immune system to destroy any remote cancer cells."

Roger Dumoulin-White, president and chief executive officer of Theralase, stated: "I am delighted that Theralase continues to make great strides in the development and more comprehensive intellectual protection of our anti-cancer PDC technology. With the filing of this patent submission, Theralase is pursuing a broad intellectual property coverage strategy on both our PDC technology and the customized laser systems that activate them to ensure long-lasting patent protection for our shareholders. Our goal is to provide a fully customizable PDC solution to each and every patient inflicted with cancer, whereby, we provide the personalized PDT to destroy their cancer permanently and prevent its recurrence, all in a single treatment."

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.